Council Decision (EU) 2022/391 of 3 March 2022 on the position to be taken on behalf of the European Union in the 65th session of the Commission on Narcotic Drugs on the scheduling of substances under the Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol, and the Convention on Psychotropic Substances of 1971
Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗
The position to be taken on behalf of the Union by the Member States in the 65th session of the Commission on Narcotic Drugs from 14 to 18 March 2022, when that body is called upon to adopt decisions on the addition of substances to the Schedules of the United Nations Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol, and the United Nations Convention on Psychotropic Substances of 1971, shall be that set out in the Annex to this Decision.
The position referred to in Article 1 shall be expressed by the Member States that are members of the Commission on Narcotic Drugs, acting jointly in the interest of the Union.
This Decision is addressed to the Member States in accordance with the Treaties.
ANNEX Position to be taken by the Member States which are members of the Commission on Narcotic Drugs, acting jointly in the interest of the Union, during the 65th session of the Commission on Narcotic Drugs from 14 to 18 March 2022 on the scheduling of substances: (1) Brorphine is to be included in Schedule I of the Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol. (2) Metonitazene is to be included in Schedule I of the Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol. (3) Eutylone is to be included in Schedule II of the Convention on Psychotropic Substances of 1971.
Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.